Telix announces QDOSE platform partnership for personalised dosimetry in radiopharmaceutical therapy

Telix has entered into an agreement to commercially partner the QDOSE dosimetry software platform with Germany-based contract research organisation Advanced Pharmaceutical Services Forschungsgesellschaft and its partner Stockholm-based Quantinm.

Telix said QDOSE is a validated, versatile software platform enabling reliable estimation of patient-specific dosimetry for therapeutic and diagnostic radiopharmaceuticals.

The company said it intends to integrate the QDOSE platform into its therapeutic radiopharmaceutical programs and clinical collaborations to enable the development of personalised treatment regimens.

“Personalised radiopharmaceutical therapy administration based on individual patient dosimetry has the potential to improve clinical outcomes by optimising treatment response while reducing effects on normal healthy organs and optimising the use of isotope supply chains,” it said.

QDOSE supports dosimetry calculations using planar imaging, tomographic imaging, single/multi-time point imaging, and hybrid combinations. QDOSE incorporates additional tools for attenuation and background correction.

The QDOSE platform will be integrated with Telix’s artificial intelligence (AI) products as an accessible tool for clinicians and third-party commercial drug developers. QDOSE® has received 510(k) clearance from the US FDA and is Conformité Européenne marked for clinical use within the EU.

Telix managing director and Group CEO Dr Christian Behrenbruch said, “In nuclear medicine, dosimetry analysis is used to calculate the absorbed dose of radiation received by different parts of the body. Rapid, reliable and personalised dosimetry is becoming an increasingly important future direction of cancer care and regulatory authorities now expect to see dosimetry analysis. QDOSE has an excellent performance track record and we are committed to positioning QDOSE as a new industry standard in dosimetry analysis.”

Telix said the arms’ length up-front transaction consideration is non-material. It will pay undisclosed product royalties and fees on product sales.

/Public Release. View in full here.